May 2026
Sandra E. Kurtin, PhD, A... Market Share Analysis for May 2026
Sandra E. Kurtin, PhD, ANP-C, AOCN, of the University of Arizona Cancer Center, discusses the findings of a retrospective study that assessed the use of first-line ibrutinib for chronic lymphocytic leukemia in the United States. Although the agent was increasingly used in this setting, early discontinuation was more common than reported, suggesting clinical decision support tools and care delivery approaches should be explored (Abstract 797).
Industry: N/A
Sandra E. Kurtin, PhD, ANP-C, AOCN, o... (including company regionals)
See more website traffic and engagement information- jadpro.com
Total visits to Sandra E. Kurtin, PhD, ANP-C, AOCN, o...'s top domains
Understand Sandra E. Kurtin, PhD, ANP-C, AOCN, o... market share and potential market reach.
Total visits last 3 months
Subsidiaries Breakdown
Avg. visit duration in Sandra E. Kurtin, PhD, ANP-C, AOCN, o...'s top domains
Analyze Sandra E. Kurtin, PhD, ANP-C, AOCN, o... engagement metrics.
Average visit duration last 3 months
Subsidiaries Breakdown
Avg. pageviews on Sandra E. Kurtin, PhD, ANP-C, AOCN, o...'s top domains
See how Sandra E. Kurtin, PhD, ANP-C, AOCN, o... keep users engaged, nurture their interest, and encourage them to take the next step.
Average page views last 3 months
Subsidiaries Breakdown
